08:25 AM EDT, 08/22/2024 (MT Newswires) -- Cognition Therapeutics ( CGTX ) said Thursday that its SEQUEL study of its lead Alzheimer's drug candidate CT1812 showed that treated participants exhibited "consistent" trends of improvement in brain wave patterns and connectivity between brain regions.

The study involved 16 participants with mild-to-moderate Alzheimer's. CT1812 was well tolerated, with no severe adverse events reported, the company said.

Cognition Therapeutics ( CGTX ) shares were down 0.4% in recent premarket activity.

Price: 0.7685, Change: +0.02, Percent Change: +2.49